Filter
Exclude
Time range
-
Near
We are searching distributor all over the owld to enlarge our sale market,For more information please visit feiyuebio.com #research #business #quality #lifesciences #Elisakits #HumanRUO #laboratory #lab #medical #technologist #doctor #Interleukin
0
0
0
0
The cytokine #Interleukin-6 drives osteoarthritis through multiple pathways in mouse models, according to new work that sheds light on sex-specific mechanisms in the condition and suggests at new therapeutic targets. @Duke_PCB @MatthewJHilton #Physiology fcld.ly/w26p5h6
0
2
0
5
Jamie Swaney, Ph.D., VP of Fibrosis & Translational Biology at Lassen Therapeutics, will discuss the antibody-mediated blockade of #interleukin-11 signaling for IPF & other fibrosing lung diseases. #drugdiscovery #lungresearch #earlyhumaninsights attendee.gotowebinar.com/reg…
0
2
0
2
Interleukin Inhibitors Market Top Key Players, and, Applications Analysis 2019-2026 Get More Information@ alliedmarketresearch.com/req… #interleukin #inhibitorsmarket #healthcare #marketresearch #AMR #Investment Read More@ amarketplaceresearch.com/202…
0
0
0
0
#Interleukin (IL)-15 immunotherapy: A novel non-steroidal approach to treat #allergen-induced airway obstructions For more info;scholarscentral.org/submissi… Submission opens at: pulmonology@scienceresearchpub.org
0
0
0
0
| Dermatology Reports | #Alopecia areata and #interleukin (IL)-17A A study suggests that IL-17A may play an important role in determining the #pathogenesis of AA and may serve as a valuable clinical #biomarker of this #disease. doi.org/10.4081/dr.2021.9398
0
0
0
3
#RecommendedPaper Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor By: Massimo Bertinaria, et al. 👉mdpi.com/1420-3049/26/13/397… 📌#NLRP3 #inhibitors #pyroptosis #interleukin #ATP #hydrolysis #simulations
0
0
0
0
Human IL-15(Interleukin 15) ELISA Kit Catalog NO.: FY-EH4623 #feiyuebio #elisakit #Interleukin #sandwich elisa kit #biology #manufacturer feiyuebio.com
0
0
0
0
Abbvie’s Skyrizi (risankizumab-rzaa) scored its third indication from the FDA, now approved to be the first and only specific #interleukin-23 (IL-23) inhibitor for the treatment of adults with moderate to severe #Crohn’s disease lnkd.in/da25tavU
0
0
0
0